Replies to post #387274 on Elite Pharmaceuticals Inc (ELTP)

[The ELTP King]

Takeda's Adderall XR revenue for Fiscal Year 2022 based on current exchange rates:

$194,052,229

Takeda's Adderall XR revenue for Fiscal Year 2023 Q1 based on current exchange rates:

$91,591,560 (117.7% increase year over year)

Prasco obtained Teva/Shire Adderall xr on 2016 according to my search. Apparently Takeda has been manufacturing the product for them. Major pharmacies did not renew their purchases in 2021 with the exception of Walmark.

It appears that the manufacturing agreement with Takeda will expire at the end of this year and Elite will become its new manufacturer of the Authorized generic of Adderall XR starting on January 1.

It may be that Prasco opted to sign with Elite since they can make the drug cheaper than competitors. Perhaps a review of TAK financials will give a clue as to their manufacturing revenue from XR.